What are Shigella Infections?
Shigella Infections are a major global health problem and the main sign is diarrhea, which often is bloody. In addition to this, symptoms may include fever, as well as stomach pain.
How will Shigella Infections market change in upcoming years?
The market is expected to experience a positive growth in the coming years owing to the already prescribed products along with the launch of emerging therapies in the coming years. The key driver for the surge in market size would be the direct consequences of rise in the number of incident cases.
The Shigella Infections market forecast report helps to build the detailed comprehension of the historic, current, and forecasted Shigella Infections market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
The report also provides Shigella Infections market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
For more information on Shigella Infections market size, click here @ https://www.delveinsight.com/report-store/shigella-infections-market
Which companies are in Shigella Infections pipeline?
The dynamics of Shigella Infections market is anticipated to change in the coming years owing to the increase in the initiatives towards control of drug-resistance, emergence of new candidates for the management of this situation during the forecast period of 2020–2030. Some of the key players, such as LimmaTech Biologics AG, GlaxoSmithKline, Immuron and others have recently entered in the therapeutic market of Shigella Infections at a global level.
GlaxoSmithKline is investigating GSK3536852A vaccine in phase II. The purpose of this study was to evaluate the efficacy, safety and immunogenicity of the GSK3536852A vaccine, which was designed to protect against Shigella Infections caused by S. sonnei. For this vaccine the new Generalized Modules for Membrane Antigens (GMMA) platform technology developed by GlaxoSmithKline Vaccines Institute for Global Health (GVGH) was used. The GSK3536852A vaccine has been tested in two Phase I dose escalation studies in Europe to assess its safety and immunogenicity via three routes of administration: intramuscular (IM), intranasal (IN) and intradermal (ID). The results from the first study (dose escalation with IM vaccination) have shown that the vaccine has an acceptable safety profile and is well-tolerated up to a dose of 100 micrograms (µg). The results from the second study (dose escalation with ID, IN and IM vaccination) showed that GSK3536852A vaccine is well-tolerated also when administered by the ID and IN routes of vaccination. However, immunogenicity data have shown that GSK3536852A vaccine administered by the ID and IN routes is not as immunogenic as GSK3536852A vaccine administered by the IM route. Therefore, it has been decided to proceed with the clinical development program of this vaccine only using the IM vaccination route. In terms of dosage, the regimen tested in Phase I studies (three doses given one month apart) did not show any significant benefit from the third dose in terms of immunogenicity, therefore a two dose schedule was selected for next studies (as per ClinicalTrials.gov).
Furthermore, another product named Shigella4V is under development by LimmaTech Biologics AG. Shigella4V is a tetravalent bioconjugate vaccine including O antigen-polysaccharides of the most predominant Shigella serotypes. In September 2019, LimmaTech Biologics AG announced the start of a Phase I/II clinical trial in Kenya of a 4-valent candidate vaccine to help prevent diarrheal disease caused by the Shigella bacteria in children and infants in low and middle-income regions. This study is conducted in collaboration with GSK.
Apart from this, Immorun candidates Travelan and IMM-124E demonstrates broad-spectrum antimicrobial properties. Travelan has shown to target common bacterial antigens present on Enterotoxigenic Escherichia coli (ETEC) and Shigella. The company plans to initiate phase III trial for IMM-124E to prevent travelers’ diarrhea.
The pipeline of the Shigella Infections is mainly focused on the treatment of drugs resistance infections. The current scenario also anticipates a positive shift in the market for a study period.
Click here to know more on Shigella Infections Companies @ https://www.delveinsight.com/report-store/shigella-infections-pipeline-insight